Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

Inclusion Criteria:

* 1\. Diagnosed as stage II-III pancreatic ductal adenocarcinoma patients by pathologic histology;
* 2\. Pancreatic cancer after radical resection;
* 3\. Eastern Cooperative Oncology Group Performance Status less than 2;
* 4\. Without radiotherapy or neoadjuvant chemotherapy;
* 5\. The man or the gestation and lactation women Age between 18 to 80 years old;
* 6\. Bone marrow functioned well: ANC more than 1.5\*10\^9/ L, PLT more than 100\*10\^9/LHgb more than 9 g/dL;
* 7\. Blood biochemical indicators: AST（SGOT）less than 1.5 ULNALT（SGPT）less than 1.5 ULN, TBIL less than 1.5 ULN;
* 8\. PT and PPT are in normal ranges;
* 9\. Three months prior to clinical research did not receive any other clinical research trials;
* 10\. patients are voluntary, and willing to sign informed consent.

Exclusion Criteria:

* 1\. Patients with other malignant tumors in the past five years;
* 2\. Active viral or bacterial infection and cannot be controlled with appropriate anti-infection treatment;
* 3\. Known as HIV infection, active hepatitis B virus or hepatitis C virus infection;
* 4\. Known allergy to any kind of component of study drugs;
* 5\. History of connective tissue disease(Such as lupus, scleroderma, nodular arteritis);
* 6\. Patients with a history of interstitial pneumoniaSlowly progressive difficulty in breathing and hoose Sarcoidosissilicosis Fibrose pulmonaire idiopathiquehylactic pneumonia or A variety of allergy;
* 7\. Suffering from mental illness or other illness, such as heart or lung disease, diabetes, etc. that can not be controlled, and can not cope with study treatment and monitoring requirements;
* 8\. At the same time Patients participate in any other use of interventional medicine clinical research or checkers.